390 related articles for article (PubMed ID: 20469779)
21. Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal-bolus regimen.
Christensen TE; Gundgaard J; Pilgaard T
J Med Econ; 2011; 14(4):477-85. PubMed ID: 21668290
[TBL] [Abstract][Full Text] [Related]
22. Insulin glargine dosing before next-day surgery: comparing three strategies.
Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
[TBL] [Abstract][Full Text] [Related]
23. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
Home PD; Fritsche A; Schinzel S; Massi-Benedetti M
Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629
[TBL] [Abstract][Full Text] [Related]
25. Insulin glargine: an updated review of its use in the management of diabetes mellitus.
Dunn CJ; Plosker GL; Keating GM; McKeage K; Scott LJ
Drugs; 2003; 63(16):1743-78. PubMed ID: 12904090
[TBL] [Abstract][Full Text] [Related]
26. BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA.
Bueno E; Benitez A; Rufinelli JV; Figueredo R; Alsina S; Ojeda A; Samudio S; Cáceres M; Argüello R; Romero F; Echagüe G; Pasquel F; Umpierrez GE
Endocr Pract; 2015 Jul; 21(7):807-13. PubMed ID: 26121460
[TBL] [Abstract][Full Text] [Related]
27. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians.
Brod M; Rana A; Barnett AH
Curr Med Res Opin; 2012 Dec; 28(12):1947-58. PubMed ID: 23150950
[TBL] [Abstract][Full Text] [Related]
28. Reducing hypoglycaemia with insulin analogues.
Heller S
Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
[TBL] [Abstract][Full Text] [Related]
29. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
30. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
[TBL] [Abstract][Full Text] [Related]
31. Peri-operative management of glucose.
Ag U; Prusty V
J Indian Med Assoc; 2010 Jan; 108(1):52-5. PubMed ID: 20839582
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.
Hsia E; Seggelke SA; Gibbs J; Rasouli N; Draznin B
Nutr Clin Pract; 2011 Dec; 26(6):714-7. PubMed ID: 22205560
[TBL] [Abstract][Full Text] [Related]
33. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy.
Barnett AH
Curr Med Res Opin; 2010 Jun; 26(6):1333-42. PubMed ID: 20370379
[TBL] [Abstract][Full Text] [Related]
34. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and feasibility of basal-bolus insulin regimens and a discharge-strategy in hospitalised patients with type 2 diabetes--the HOSMIDIA study.
Pérez A; Reales P; Barahona MJ; Romero MG; Miñambres I;
Int J Clin Pract; 2014 Oct; 68(10):1264-71. PubMed ID: 25269951
[TBL] [Abstract][Full Text] [Related]
36. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial.
Strojek K; Shi C; Carey MA; Jacober SJ
Diabetes Obes Metab; 2010 Oct; 12(10):916-22. PubMed ID: 20920045
[TBL] [Abstract][Full Text] [Related]
37. Retrospective Evaluation of Glycemic Control With Basal-Bolus or Neutral Protamine Hagedorn Insulin Regimens in Patients Receiving Continuous Enteral Nutrition Therapy in Medicine Wards.
Hijaze D; Szalat A
Nutr Clin Pract; 2017 Aug; 32(4):557-562. PubMed ID: 28760108
[TBL] [Abstract][Full Text] [Related]
38. Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?".
Ghosal S; Sinha B; Majumder A; Das AK; Singh AK; Ghoshdastidar B; Maji D; Goyal G; Mukherjee JJ; Gangopadhyay KK; John M; Chatterjee S; Jaggi S; Ray S; Majumdar S; Sharma SK
J Assoc Physicians India; 2017 Jul; 65(7):51-62. PubMed ID: 28792170
[TBL] [Abstract][Full Text] [Related]
39. [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective].
Jermendy G; Kovács G
Orv Hetil; 2018 Dec; 159(50):2122-2128. PubMed ID: 30545262
[TBL] [Abstract][Full Text] [Related]
40. Insulin preparations with prolonged effect.
Owens DR
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
